Complete title: APEC1621F, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Research Study Number | APEC1621F |
Principal Investigator | Navin Pinto, MD |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | APEC1621F |
Contact | Navin Pinto, MD |
Telephone | 206/987-2106 |
Keywords: Central Nervous System (CNS); Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Immunoproliferative Disorders; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Immune System Diseases; Histiocytoma; Nervous System Diseases; Neuroectodermal Tumors, Primitive, Peripheral
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.